DDInter1215 DDInter1376
Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome. The two marketed forms of mifepristone are Mifeprex® (mifepristone 200mg) and Korlym™ (mifepristone 300mg). Currently under investigation for use in psychotic depression (phase 3 trials).
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Mifepristone {u} (Compound) binds {v} (Gene) CYP3A5
Mifepristone {u} (Compound) upregulates {v} (Gene) CDK6
Mifepristone {u} (Compound) is included by {v} (Pharmacologic Class) Progestational Hormone Receptor Antagonists
Mifepristone {u} (Compound) downregulates {v} (Gene) ATP6V1D
Mifepristone {u} (Compound) causes {v} (Side Effect) Toxic shock syndrome
Mifepristone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bexarotene
Mifepristone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Mifepristone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naldemedine
Mifepristone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Chloramphenicol
Mifepristone {u} may lead to a major life threatening interaction when taken with {v} Daunorubicin
Mifepristone (Compound) binds CYP3A5 (Gene)
Mifepristone (Compound) upregulates CDK6 (Gene)
Mifepristone (Compound) is included by Progestational Hormone Receptor Antagonists (Pharmacologic Class)
Mifepristone (Compound) downregulates ATP6V1D (Gene)
Mifepristone (Compound) causes Toxic shock syndrome (Side Effect)
Mifepristone may cause a minor interaction that can limit clinical effects when taken with Bexarotene
Mifepristone may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol
Mifepristone may lead to a major life threatening interaction when taken with Daunorubicin